Advocacy at a Glance
November 7, 2016
Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA.
- FDA and the Elections: Many Unknowns. In previous Analysis and Commentary columns, we have focused on Presidential transition and its impact on FDA and looked at potential scenarios regarding leadership on the Appropriations Committees. This week we look beyond the election and reprise an earlier column on the upcoming appropriations battles that will restart when Congress re-convenes the week of November 14 for its Lame Duck session.
- Alliance Annual Member Meeting/2016 Election Re-Cap is Tuesday, November 15 at 1 p.m. This year, we will be repeating our very successful post-election analysis by the bipartisan political leadership team at Akin Gump. Former Senator Kay Hagan (D, NC), Former Congressman Vic Fazio (D, CA), former Congressman Tom Loeffler (R, TX), and longtime Republican insider Jamie Tucker will provide their perspective on the election result. This one always fills the room to capacity, so let Lynnette Bechtel know if you will be joining.
- Alliance Meetings with FDA Planned for November. We have a meeting at White Oak planned with Dr. Rachel Sherman, Deputy Commissioner for Medical Products and Tobacco, on November 15 in the morning. We also have a meeting scheduled with Dr. Peter Marks, new Director of the CBER, in the morning on November 16. Let Lynnette know, if you are interested in joining either meeting.
- Confirmed: FDA Regulates 20% of Consumer Spending. You have heard the statistic used by the Alliance for years: FDA regulates 20% of consumer spending in the U.S. Now, we have confirmation of this from FDA’s economic analysis staff, as covered this week in FDA Voice, the agency’s blog.